ArticlePediatric research2026
Age-stratified evaluation of sublingual immunotherapy outcomes in children with allergic rhinitis.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSublingual immunotherapy (SLIT) consistently ameliorates pediatric allergic rhinitis (AR); the developmental stage-dependent efficacy remains equivocal. This study interrogated whether symptomatic improvement after SLIT differs among preschool, prepubertal, and pubertal cohorts.
methodsWe enrolled children with AR (aged 4-14 years) receiving SLIT and stratified them into three age groups: preschool (4-6 years), prepubertal (7-9 years), and pubertal (10-14 years). Nasal symptoms and total nasal symptom scores (TNSS) were evaluated at baseline and at different time points during treatment.
resultsA total of 134 patients were included (71 preschool, 41 prepubertal, 22 pubertal). All age groups showed significant improvement in nasal symptoms post-SLIT (P < 0.05), but a pronounced "younger-age advantage" was observed. Preschool (4-6 years) children experienced a 14.4% greater improvement in TNSS at 12 months compared to pubertal children (P < 0.05). The preschool and prepubertal groups achieved rapid symptom relief within 12 months, with subsequent stabilization, whereas the pubertal group required 24 months to attain comparable efficacy and exhibited poorer control of nasal itching.
conclusionsSLIT efficacy in pediatric AR is age-dependent, with younger patients deriving greater benefits and pubertal patients requiring extended treatment duration (≥3 years). These findings support age-stratified therapeutic strategies and provide critical evidence for personalized SLIT regimens. IMPACT: This study reveals that SLIT efficacy for pediatric allergic rhinitis is age-dependent, with younger children (preschool and prepubertal) experiencing faster and more significant symptom improvement compared to pubertal children. It highlights the need for age-stratified treatment strategies, suggesting that SLIT should be prioritized for preschool children to prevent disease progression and that pubertal patients may require extended treatment duration (≥3 years) and adjunctive therapies for optimal outcomes. These findings fill a critical knowledge gap regarding age-specific responses to SLIT and provide evidence-based support for personalized treatment regimens in pediatric allergic rhinitis management.
Identifiers
41975077What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.